Prula-cel Shows Early Promise in Lupus

Adicet Bio reports 12-month remission and renal response data for its allogeneic gamma delta CAR T therapy

1

In a Phase I study, 22 patients with SLE, including 16 with lupus nephritis, were efficacy-evaluable after at least 6 months of follow-up.
2

At 12 months, 54% of evaluable patients achieved DORIS remission, and 50% of evaluable patients with lupus nephritis achieved complete renal response.
3

All efficacy-evaluable patients discontinued immunosuppressants, and all but 1 reduced corticosteroids to 5 mg or less of prednisone equivalent daily.
4

Among 24 safety-evaluable patients, no CRS above grade 2 or cases of neurotoxicity, IEC-HS, graft-versus-host disease, or dose-limiting toxicity were reported.
5

Adicet plans to begin start-up activities in the fourth quarter of 2026 for a single-arm pivotal study in lupus nephritis patients with inadequate responses to at least 2 immunosuppressants.

1